Know Cancer

forgot password

Dexmedetomidine and Hypoxic Pulmonary Vasoconstriction in Thoracic Surgical Procedure and One-Lung Ventilation(OLV)

19 Years
Not Enrolling
Lung,Esophageal Cancers, Airway Reconstruction, Chest Wall Disorders

Thank you

Trial Information

Dexmedetomidine and Hypoxic Pulmonary Vasoconstriction in Thoracic Surgical Procedure and One-Lung Ventilation(OLV)

To collect data on the effects of Dexmedetomidine(DEX)(0.3mcg/kg loading dose followed by an
infusion of 0.3mcg/kg/hr)on Hypoxic pulmonary vasoconstriction when administered to patients
during surgery with one lung ventilated thoracic procedures. Dexmedetomidine has both
vasoconstricting and vasodilatatory effect on peripheral vasculature but its effect on
pulmonary vessels is not known. If it is predominantly a vasodilator on pulmonary vessels it
can inhibit hypoxic pulmonary vasoconstriction and will increase shunting of venous blood to
arterial circulation without oxygenation. If our study proves it to be a vasodilator for
pulmonary vessels then it will not be wise to use it in thoracic procedure with one lung
ventilation. If our study proves that it is a vasoconstrictor for pulmonary vessels, then it
will be an excellent adjunct to other anesthetic agents during one lung ventilation.

Inclusion Criteria:

1. Subject is > 18 years of age.

2. Subject is American Society of Anesthesiologists (ASA) Physical Status I, II, III, or

3. If female, subject is non-lactating and is either:

- Not of childbearing potential, defined as post-menopausal for at least 1 year or
surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or

- Of childbearing potential but is not pregnant at time of baseline and is
practicing one of the following methods of birth control: oral or parenteral
contraceptives, double-barrier method, vasectomized partner, or abstinence from
sexual intercourse.

4. Subject requires thoracic surgical procedure .

5. Subject (or subject's legally authorized representative) has voluntarily signed and
dated the informed consent document approved by the Institutional Review Board.

Exclusion Criteria:

1. Subject has received general anesthesia within 7 days prior to study entry, has
received any experimental drug within 30 days prior to study drug administration, or
has been previously enrolled in this study.

2. Subject has central nervous system (CNS) disease with an anticipated potential for
increased intracranial pressure, an uncontrolled seizure disorder and/or known
psychiatric illness that could confound a normal response to sedative treatment.

3. Subject has received treatment with an alpha-2 agonist or antagonist within 14 days
of the scheduled surgery/procedure.

4. Subject for whom opiates, benzodiazepines, DEX or other alpha-2 agonists are

5. Subject has received an IV opioid within one hour, or PO/IM opioid within four hours,
of the start of study drug administration.

6. Subject has acute unstable angina, acute myocardial infarction documented by
laboratory findings in the past six weeks, heart rate < 50 bpm, SBP < 90 mmHg, or
third-degree heart block unless patient has a pacemaker.

7. Subject has known elevated SGPT (ALT) and/or SGOT (AST) values of > 2 times the upper
limit of normal (ULN) within the two months prior to screening, and/or a history of
liver failure.

8. Subject has any other condition or factor which, in the Investigator's opinion, might
increase the risk to the subject.

9. On vasodilators, i.e.,nitroglycerin, nitroprusside, or ACE inhibitors

10. on vasopressors, i.e, norepinephrine,epinephrine, or vasopressin

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Cross-Sectional

Outcome Measure:

The primary outcome will be changes in oxygenation measured by the PaO2 during one lung ventilation

Outcome Time Frame:

During thoracic surgical procedure

Safety Issue:


Principal Investigator

joseph tobias, md

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Missouri-Columbia


United States: Institutional Review Board

Study ID:

1124100 Hospira



Start Date:

March 2009

Completion Date:

November 2009

Related Keywords:

  • Lung,Esophageal Cancers
  • Airway Reconstruction
  • Chest Wall Disorders
  • Thoracic surgery one lung ventilation
  • Esophageal Diseases
  • Esophageal Neoplasms



University Of Missouri-Columbia Columbia, Missouri  65212